Dear Dr. Roach • My wife went blind in her left eye suddenly last October, and a biopsy showed temporal arteritis. She was started on high-dose prednisone, and after four ...

Relapse should be managed as follows: Return of headache should be treated with the most recent previous higher steroid dose; Jaw claudication requires 40–60 mg prednisolone; ...

Disease flares in patients with giant-cell arteritis and polymyalgia rheumatica are common during the tapering of glucocorticoids and often respond to a 10 to 20% increase in dose.

Giant cell arteritis, also called temporal arteritis, is a disease that causes your arteries -- blood vessels that carry oxygen from your heart to the rest of your body -- to become inflamed. It ...

A clue to the diagnosis of giant-cell arteritis is the development of jaw muscle pain and weakness after a few minutes of chewing gum.

Practice implications: Biopsy-proven temporal arteritis should continue to be treated initially with high-dose prednisone therapy. Concurrent treatment with methotrexate can reduce the duration and ...

The temporal arteries are tender and swollen bilaterally. She cannot elevate her shoulders above her head, because of stiffness and pain. Her GP suspects a diagnosis of giant cell arteritis (GCA), ...

- If temporal arteritis is suspected, urgent treatment should be started with prednisolone 40-60mg daily to prevent visual loss. 3,4 - If there are no contraindications, low dose aspirin 75mg/day ...

In giant cell arteritis, there is no good alternative, and the prednisone dose needs to be tapered off slowly to prevent recurrence or flare-up of the condition. This requires a seasoned clinician.

Temporal arteritis (also called giant cell arteritis) is an inflammation of arteries, and it's often a companion illness to polymyalgia. The name comes from the temporal artery, the artery at the ...

GCA relapse requires a high dose of (40–60 mg) prednisolone. Beyond two relapses, steroid-sparing agents such as methotrexate or azathioprine are usually used, but leflunomide has shown promise ...